OakChart

Regentis Biomaterials Ltd

RGNTHealthcare·Medical Instruments & Supplies·Israel·Nano·AMEX·Nov 11 • 11:27 AM ET

1.28-0.05 (-3.76%)
2026-11-11 17:37 CET
Market cap
9.34 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-13.04 USD m
Free cash flow, TTM
-3.88 USD m
EPS diluted, TTM
-2.45
P/E
-
Compare

Price

RGNT against its 20, 50 and 200-day averages
2050200
5.0010.0015.0093.3M186.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RGNTclose 1.2820-day 1.3550-day 1.65200-day 2.761.2852w high

91.7% under the 52-week high of 15.50 on 15 Jun 2026. 52-week low 1.16 on 6 Nov 2026. Last 15 sessions, 45.7% high to low

Profile

RGNT
52-week range, 1% of the way up
1.1615.50

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Employees10
IPODec 04, 2025
ATR, 14d0.14
Rel volume1.36
Short float0.14%
Insider own31.06%
Inst own15.86%

Snapshot

6 groups

Valuation

Index-
Market Cap8.99M
Enterprise Value0.07M
Income-13.04M
Sales0.00M
Book/sh1.09
Cash/sh1.27
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees10
IPODec 04, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.17
P/C1.00
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.62
Current Ratio5.62
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.45
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y11.45% -71.58%
Sales past 3/5Y- -
EPS Y/Y TTM-113.63%
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own31.06%
Insider Trans0.00%
Inst Own15.86%
Inst Trans-4.58%
ROA-265.04%
ROE-
ROIC-169.11%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.08%
SMA50-22.49%
SMA200-53.63%
Trades-

Technical

Shs Outstand4.93M
Shs Float4.84M
Short Float0.14%
Short Ratio0.13
Short Interest0.01M
52W High15.50 -91.74%
52W Low1.16 10.34%
Volatility17.68% 10.44%
ATR (14)0.14
RSI (14)39.73
Beta-
Rel Volume1.36
Avg Volume51.10K
Volume24,855

Performance

Perf Week-3.03%
Perf Month-21.23%
Perf Quarter-32.63%
Perf Half Y-37.71%
Perf YTD-81.01%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price10.00
Prev Close1.33
Price1.28
Change %-3.76%

Peers

Mkt cap
TickerCompanyMkt cap
ANIKAnika Therapeutics Inc186.06M
BVSBioventus Inc933.61M
NXGLNexgel Inc12.83M
MDXGMimedx Group Inc484.91M
SINTSINTX Technologies Inc12.32M
ORGOOrganogenesis Holdings Inc126.18M
ELUTElutia Inc40.76M
XTNTXtant Medical Holdings Inc38.93M
AXGNAxogen Inc3.13B
KIDSOrthoPediatrics corp882.01M

News

latest 14 of 76
  • Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel (ACCESSWIRE) +6.72%
  • Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal (ACCESSWIRE)
  • Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City (ACCESSWIRE) -5.88%
  • Regentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair (NewMediaWire)
  • Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update (ACCESSWIRE)
  • Loading…
  • Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC (NewMediaWire)
  • Regentis Biomaterials (RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks (NewMediaWire)
  • Regentis Biomaterials (RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market (NewMediaWire) +5.26%
  • Regentis Biomaterials (RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair (NewMediaWire) +7.47%
  • Regentis Biomaterials (RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C (NewMediaWire)
  • Regentis Biomaterials (RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market (NewMediaWire) +5.10%
  • Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology (ACCESSWIRE) -15.97%
  • Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process (NewMediaWire) -8.64%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-24.160--0.00-
2026FY--0.680--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYS2026-02-271000.000.000.00
2026FYE2026-02-27100-0.68-0.68-0.68

Estimate history

EPS, annual-0.305-0.8480.964-2.644
Period2020202320242025
EPS, quarterly
Period
Sales, annual0000
Period2020202320242025
Sales, quarterly
Period
Shares, annual1.3514.9294.9295.179
Period2020202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2020FY
Total Revenue0.000.000.000.00-0.00
Cost of Goods Sold Incl. D&A0.010.000.000.00-0.00
Gross Profit-0.010.000.000.00-0.00
Selling, General and Administrative Excl. Other8.926.97-0.931.93-0.36
Research and Development1.350.33-1.640.81-0.33
Other Operating Expense0.000.000.000.00-0.00
Operating Income-8.93-6.970.93-1.93--0.36
Interest Expense1.901.980.170.18-0.00
Unusual Expense2.204.78-3.951.96-0.08
Net Income Before Taxes-13.02-13.654.80-4.13--0.41
Income Taxes0.000.000.000.00-0.00
Consolidated Net Income-13.02-13.654.80-4.13--0.41
Net Income From Continuing Operations-13.02-13.654.80-4.13--0.41
Net Income-13.04-13.694.75-4.18--0.41
EPS (Recurring)-1.93-2.000.40-0.57--0.26
EPS (Basic, Before Extraordinaries)-2.45-2.640.96-0.85--0.30
EPS (Diluted)-2.45-2.640.96-0.85--0.30
EBITDA-8.92-6.970.93-1.93--0.36
Non-Operating Income (Expense)0.000.070.10-0.07-0.03
Other After Tax Adjustments0.000.000.000.00-0.00
Stock Option Compensation Expense-7.04----
Shares Outstanding7.025.184.934.93-1.35
Market Capitalization9.349.3435.48---

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12021S22021S1
Total Revenue0.000.000.000.000.00-0.000.00
Cost of Goods Sold Incl. D&A0.010.000.000.000.00-0.000.00
Gross Profit-0.010.000.000.000.00-0.000.00
Selling, General and Administrative Excl. Other2.396.530.440.94-1.87-0.420.25
Research and Development1.200.150.180.53-2.17-0.130.21
Other Operating Expense0.000.000.000.000.00-0.000.00
Operating Income-2.40-6.53-0.44-0.941.87--0.42-0.24
Interest Expense0.201.700.210.070.01-0.02-
Unusual Expense0.002.202.581.40-5.34-4.68-0.22
Net Income Before Taxes-2.60-10.42-3.23-2.417.21--5.12-0.02
Income Taxes0.000.000.000.000.00-0.000.00
Consolidated Net Income-2.60-10.42-3.23-2.417.21--5.12-0.02
Net Income From Continuing Operations-2.60-10.42-3.23-2.417.21--5.12-0.02
Net Income-2.60-10.44-3.23-2.437.18--5.12-0.02
EPS (Recurring)-0.44-1.72-0.29-0.290.70--1.37-0.13
EPS (Basic, Before Extraordinaries)-0.44-2.02-0.65-0.491.46--3.79-0.02
EPS (Diluted)-0.44-2.02-0.65-0.491.46--3.79-0.02
EBITDA-2.39-6.53-0.44-0.941.87--0.42-0.24
Non-Operating Income (Expense)0.000.000.000.000.00-0.000.00
Stock Option Compensation Expense0.46-------
Shares Outstanding7.025.184.934.934.93-1.351.35
Market Capitalization9.3434.9135.48-----

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2020FY
Cash & Short Term Investments7.380.230.34-1.38
Short Term Receivables0.230.070.01-0.01
Inventories0.000.000.00-0.00
Other Current Assets0.010.180.01-0.00
Total Current Assets7.620.480.36-1.39
Net Property, Plant & Equipment0.000.000.00-0.00
Total Investments and Advances0.000.000.00-0.00
Intangible Assets0.000.000.00-0.00
Other Assets0.000.000.00-0.00
Total Assets7.620.480.36-1.39
Short Term Debt Incl. Current Port. of LT Debt1.204.950.21-0.00
Accounts Payable0.270.250.35-0.33
Other Current Liabilities1.411.292.58-1.21
Total Current Liabilities2.876.493.14-1.54
Long Term Debt0.000.007.41-0.47
Provision for Risks Charges0.000.000.00-0.00
Other Liabilities0.000.000.62-0.70
Total Liabilities2.876.4911.17-2.71
Non-Equity Reserves0.000.000.00-0.00
Preferred Stock - Carrying Value0.0035.1035.10-34.01
Common Equity4.74-41.10-45.91--35.34
Total Shareholders Equity4.74-6.01-10.81--1.33
Accumulated Minority Interest0.000.000.00-0.00
Total Equity4.74-6.01-10.81--1.33
Total Liabilities & Stockholders Equity7.620.480.36-1.39
Book Value Per Share0.92-8.34-9.31--26.16
Tangible Book Value Per Share0.92-8.34-9.31--26.16
Full-Time Employees1010---
Price to Book Ratio1.22-0.76---
Return on Assets-336.991,140.38---
Return on Invested Capital-287.69----
Quick Ratio2.650.070.11-0.90
Current Ratio2.650.070.11-0.90

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2020FY
Net Income-13.02-13.654.80-4.13--0.41
Other Funds (Non Cash)9.8512.14-3.842.20-0.14
Funds from Operations-3.17-1.510.96-1.93--0.27
Extraordinary Item0.000.000.000.00-0.00
Changes in Working Capital-0.670.13-1.600.71--0.27
Cash from Operating Activities-3.84-1.38-0.64-1.22--0.54
Capital Expenditures-0.040.000.000.00-0.00
Net Assets From Acquisitions0.000.000.000.00-0.00
Sale of Fixed Assets and Businesses0.000.000.000.00-0.00
Purchase or Sale of Investments0.000.000.000.00-0.00
Purchase of Investments0.000.000.000.00-0.00
Sale Or Maturity of Investments0.000.000.000.00-0.00
Other Uses0.000.000.000.00-0.00
Other Sources0.000.000.000.00-0.00
Cash from Investing Activities-0.040.000.000.00-0.00
Cash Dividends Paid0.000.000.000.00-0.00
Change in Capital Stock13.848.220.000.00-0.00
Repurchase of Common Pref Stock0.000.000.000.00-0.00
Sale of Common Pref Stock13.848.220.000.00-0.00
Proceedsfrom Stock Options13.848.220.000.00-0.00
Issuance or Reduction of Debt, Net-1.200.300.530.33-0.50
Change in Long Term Debt0.000.000.000.00-0.50
Issuance of Long Term Debt0.000.000.000.00-0.50
Reduction of Long Term Debt0.000.000.000.00-0.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.00
Other Financing Activities Uses0.000.000.000.00-0.00
Cash from Financing Activities12.648.520.530.33-0.50
Net Change in Cash8.767.15-0.12-0.90--0.04
Free Cash Flow-3.88-1.38-0.64-1.22--0.54
Deferred Taxes & Investment Tax Credit-0.000.000.00-0.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S1
Cash & Short Term Investments8.957.380.190.230.18-
Short Term Receivables0.000.230.000.070.00-
Inventories0.000.000.000.000.00-
Other Current Assets0.330.010.290.180.02-
Total Current Assets9.297.620.470.480.20-
Net Property, Plant & Equipment0.060.000.000.000.00-
Total Investments and Advances0.000.000.000.000.00-
Intangible Assets0.000.000.000.000.00-
Other Assets0.000.000.000.000.00-
Total Assets9.357.620.470.480.20-
Short Term Debt Incl. Current Port. of LT Debt0.011.208.164.950.15-
Accounts Payable0.200.270.260.250.23-
Other Current Liabilities1.451.411.281.290.73-
Total Current Liabilities1.652.879.716.491.11-
Long Term Debt0.020.000.000.002.54-
Other Liabilities0.000.000.000.000.15-
Total Liabilities1.672.879.716.493.80-
Non-Equity Reserves0.000.000.000.000.00-
Preferred Stock - Carrying Value0.000.0035.1035.1035.10-
Common Equity7.684.74-44.33-41.10-38.70-
Total Shareholders Equity7.684.74-9.23-6.01-3.60-
Accumulated Minority Interest0.000.000.000.000.00-
Total Equity7.684.74-9.23-6.01-3.60-
Total Liabilities & Stockholders Equity9.357.620.470.480.20-
Book Value Per Share1.090.92-8.99-8.34-7.85-
Tangible Book Value Per Share1.090.92-8.99-8.34-7.85-
Price to Book Ratio1.22-0.75-0.76---
Return on Assets-265.04-336.99-1,676.79---
Return on Invested Capital-33.77-219.65----
Quick Ratio5.622.650.050.070.18-
Current Ratio5.622.650.050.070.18-

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S1
Net Income-2.60-10.42-3.23-2.417.21-
Depreciation0.01-----
Other Funds (Non Cash)0.469.382.761.45-5.30-
Funds from Operations-2.13-1.04-0.47-0.951.91-
Extraordinary Item0.000.000.000.000.00-
Changes in Working Capital-0.670.000.130.31-1.91-
Cash from Operating Activities-2.81-1.04-0.34-0.650.01-
Capital Expenditures-0.040.000.000.000.00-
Net Assets From Acquisitions0.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.00-
Purchase of Investments0.000.000.000.000.00-
Sale Or Maturity of Investments0.000.000.000.000.00-
Other Uses0.000.000.000.000.00-
Other Sources0.000.000.000.000.00-
Cash from Investing Activities-0.040.000.000.000.00-
Cash Dividends Paid0.000.000.000.000.00-
Preferred Dividends (Cash Flow)0.00-----
Change in Capital Stock5.628.220.000.000.00-
Repurchase of Common Pref Stock0.000.000.000.000.00-
Sale of Common Pref Stock5.628.220.000.000.00-
Proceedsfrom Stock Options5.628.220.000.000.00-
Issuance or Reduction of Debt, Net-1.20-0.000.300.70-0.18-
Change in Long Term Debt0.000.000.000.000.00-
Issuance of Long Term Debt0.000.000.000.000.00-
Reduction of Long Term Debt0.000.000.000.000.00-
Net Financing Active Other Cash Flow0.000.000.000.000.00-
Other Financing Activities Uses0.000.000.000.000.00-
Cash from Financing Activities4.428.220.300.70-0.18-
Net Change in Cash1.577.19-0.040.05-0.17-
Free Cash Flow-2.84-1.03-0.34-0.650.01-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.14%0.0M4.8M51.35K
2026-10-150.25%0.0M4.8M70.05K
2026-09-300.08%0.0M4.8M90.24K
2026-09-150.14%0.0M4.8M364.00K
2026-08-310.28%0.0M4.8M5.24M
2026-08-140.17%0.0M4.8M5.32M
2026-07-311.10%0.0M3.4M5.32M
2026-07-152.39%0.1M3.4M5.38M
2026-06-305.77%0.1M2.5M5.35M
2026-06-1538.01%0.9M2.5M4.98M
2026-05-291.03%0.0M2.5M13.99K
2026-05-150.66%0.0M2.5M6.90K
2026-04-300.50%0.0M2.5M6.45K
2026-04-150.52%0.0M2.5M18.01K
2026-03-310.57%0.0M2.6M20.69K
2026-03-130.89%0.0M2.6M22.18K
2026-02-271.05%0.0M2.6M29.20K
2026-02-130.75%0.0M2.6M33.32K
2026-01-300.46%0.0M3.1M39.18K
2026-01-150.04%0.0M3.1M28.22K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-09-22EFFECTEffectiveness filing by commission orderSEC
2026-09-17POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-08-13SCHEDULE 13GSEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-20SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-07-13EFFECTEffectiveness filing by commission orderSEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-13424B3SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-09SEC
2026-07-08F-1Registration statement for certain foreign private issuersSEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-25DNotice of sales of securities on Form D (Regulation D)SEC
2026-06-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-18SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-15RWRegistration Withdrawal RequestSEC
2026-06-09F-1/ASEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-06-046-K/A2026-06-04SEC
2026-05-29FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-01F-1Registration statement for certain foreign private issuersSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Rosalind Advisors, Inc.13.55%
JANE STREET GROUP, LLC0.84%
Warberg Asset Management LLC0.83%
RENAISSANCE TECHNOLOGIES LLC0.26%
UBS Group AG0.02%
Tower Research Capital LLC0.00%

Funds

Fund% owned
-

OakChart. RGNT. Cached 15 minutes.

Some panels did not load: ratings, insider.